175 related articles for article (PubMed ID: 30880965)
1. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.
Őrfi E; Mészáros T; Hennies M; Fülöp T; Dézsi L; Nardocci A; Rosivall L; Hamar P; Neun BW; Dobrovolskaia MA; Szebeni J; Szénási G
Int J Nanomedicine; 2019; 14():1563-1573. PubMed ID: 30880965
[TBL] [Abstract][Full Text] [Related]
2. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
[TBL] [Abstract][Full Text] [Related]
3. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
[TBL] [Abstract][Full Text] [Related]
4. The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane.
Őrfi E; Hricisák L; Dézsi L; Hamar P; Benyó Z; Szebeni J; Szénási G
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885068
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
[TBL] [Abstract][Full Text] [Related]
6. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
[TBL] [Abstract][Full Text] [Related]
7. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
[TBL] [Abstract][Full Text] [Related]
8. Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion.
Milosevits G; Mészáros T; Őrfi E; Bakos T; Garami M; Kovács G; Dézsi L; Hamar P; Győrffy B; Szabó A; Szénási G; Szebeni J
Nanomedicine; 2021 Jun; 34():102366. PubMed ID: 33549818
[TBL] [Abstract][Full Text] [Related]
9. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor.
Dézsi L; Mészáros T; Kozma G; H-Velkei M; Oláh CZ; Szabó M; Patkó Z; Fülöp T; Hennies M; Szebeni M; Barta BA; Merkely B; Radovits T; Szebeni J
Geroscience; 2022 Apr; 44(2):597-618. PubMed ID: 35146583
[TBL] [Abstract][Full Text] [Related]
10. A porcine model of hemodialyzer reactions: roles of complement activation and rinsing back of extracorporeal blood.
Pethő Á; Piecha D; Mészáros T; Urbanics R; Moore C; Canaud B; Rosivall L; Mollnes TE; Steppan S; Szénási G; Szebeni J; Dézsi L
Ren Fail; 2021 Dec; 43(1):1609-1620. PubMed ID: 34882053
[TBL] [Abstract][Full Text] [Related]
11. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
[TBL] [Abstract][Full Text] [Related]
12. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
[TBL] [Abstract][Full Text] [Related]
13. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
Szebeni J; Storm G
Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
[TBL] [Abstract][Full Text] [Related]
14. Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs.
Fülöp T; Kozma GT; Vashegyi I; Mészáros T; Rosivall L; Urbanics R; Storm G; Metselaar JM; Szebeni J
J Control Release; 2019 Sep; 309():333-338. PubMed ID: 31295544
[TBL] [Abstract][Full Text] [Related]
15. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
Szebeni J; Muggia F; Gabizon A; Barenholz Y
Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
[TBL] [Abstract][Full Text] [Related]
16. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
[TBL] [Abstract][Full Text] [Related]
17. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.
Mészáros T; Csincsi ÁI; Uzonyi B; Hebecker M; Fülöp TG; Erdei A; Szebeni J; Józsi M
Nanomedicine; 2016 May; 12(4):1023-1031. PubMed ID: 26733258
[TBL] [Abstract][Full Text] [Related]
18. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
[TBL] [Abstract][Full Text] [Related]
19. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
20. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
Szebeni J
Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
